

George Fountzilas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1458905/george-fountzilas-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

9,418
citations

42
h-index

90
g-index

251
ext. papers

10,795
ext. citations

5.3
avg, IF

4.91
L-index

#	Paper	IF	Citations
244	Cancer Risks Associated With and Pathogenic Variants.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102112	2.2	7
243	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2022 , 23, 23	2.6	
242	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 32, 59-68	4.6	2
241	Lung cancer as a predominant feature in a patient with Peutz-Jeghers syndrome: Case report.. <i>Thoracic Cancer</i> , 2022 ,	3.2	0
240	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228	4	7
239	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021 , 156, 281-293	5.3	34
238	Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. <i>Anticancer Research</i> , 2021 , 41, 1793-1802	2.3	1
237	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. <i>Acta Oncologica</i> , 2021 , 60, 785-793	3.2	2
236	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021 , 2, 100042-100042	0.8	0
235	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. <i>Frontiers in Oncology</i> , 2021 , 11, 683057	5.3	
234	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	5
233	Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries. <i>Breast Cancer</i> , 2021 , 28, 1367-1382	3.4	
232	Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. <i>Human Pathology</i> , 2021 , 107, 104-116	3.7	2
231	Genotyping data of routinely processed matched primary/metastatic tumor samples. <i>Data in Brief</i> , 2021 , 34, 106646	1.2	1
230	Androgen Receptor and Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 147-156	3.3	1
229	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6156-6163	12.9	1
228	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021 , 12, 99-102	2.9	0

227	Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVER Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. <i>Cancers</i> , 2021 , 13,	6.6	10
226	When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives. <i>Cancer Genetics</i> , 2021 , 258-259, 49-50	2.3	1
225	Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
224	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. <i>Anticancer Research</i> , 2020 , 40, 929-938	2.3	3
223	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020 , 123, 355-361	8.7	5
222	Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>Biology</i> , 2020 , 9,	4.9	1
221	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 181-193	3.3	2
220	One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. <i>Journal of Medical Genetics</i> , 2020 , 57, 53-61	5.8	12
219	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 277-290	3.3	1
218	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
217	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020 , 11, 1-14	3.3	0
216	Genetic Variations of Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. <i>Anticancer Research</i> , 2020 , 40, 677-688	2.3	1
215	Is There an Independent Role of TERT and NF1 in High Grade Gliomas?. <i>Translational Oncology</i> , 2020 , 13, 346-354	4.9	7
214	Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2020 , 14, 689-700	3.3	12
213	Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 529-541	3.3	2
212	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. <i>ESMO Open</i> , 2020 , 5,	6	9
211	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, e36-e53	3	14
210	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1549-1564	7.4	9

209	Impact of Bevacizumab Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2020 , 40, 2095-2106	2.3	2
208	Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification. <i>Cancer Genetics</i> , 2019 , 237, 90-96	2.3	3
207	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019 , 4, e000441	6	2
206	PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. <i>Journal of Human Genetics</i> , 2019 , 64, 767-773	4.3	4
205	Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer. <i>Anticancer Research</i> , 2019 , 39, 2129-2138	2.3	7
204	Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 195-206	3.3	7
203	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
202	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. <i>Translational Oncology</i> , 2019 , 12, 739-748	4.9	1
201	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
200	Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e370-e384	3.8	14
199	Genotyping and Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 531-541	3.3	3
198	Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). <i>ESMO Open</i> , 2019 , 4, e000525	6	5
197	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019 , 4, e000474	6	19
196	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019 , 17, 429	8.5	4
195	Comparison of somatic variant detection algorithms using Ion Torrent targeted deep sequencing data. <i>BMC Medical Genomics</i> , 2019 , 12, 181	3.7	3
194	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019 , 19, 113-125.e4	3	5
193	Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients. <i>Gynecologic Oncology</i> , 2019 , 152, 375-386	4.9	6
192	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 411-419	4.2	2

191	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019 , 24, 521-528	5.7	28
190	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. <i>Breast Cancer Research</i> , 2018 , 20, 15	8.3	37
189	Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. <i>International Journal of Cancer</i> , 2018 , 142, 66-80	7.5	11
188	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI+ Afibercept for 6 Months Followed by Afibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 121-127	3.8	8
187	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018 , 13, e0200302	3.7	15
186	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
185	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 35623-35638	3.3	12
184	Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. <i>American Journal of Cancer Research</i> , 2018 , 8, 2-15	4.4	5
183	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018 , 18, 53-62.e3	3	5
182	Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. <i>Journal of Global Oncology</i> , 2018 , 4, 1-12	2.6	1
181	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018 , 36, 981-990	2.2	61
180	Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. <i>PLoS ONE</i> , 2018 , 13, e0208221	3.7	10
179	Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>PLoS ONE</i> , 2018 , 13, e0207707	3.7	1
178	Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. <i>Targeted Oncology</i> , 2018 , 13, 715-724	5	12
177	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018 , 7, 5066-5082	4.8	6
176	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 421-436	3.3	6
175	Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 461-471	3.3	6
174	Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. <i>Journal of Human Genetics</i> , 2018 , 63, 877-886	4.3	5

173	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Medical Oncology</i> , 2018 , 35, 101	3.7	6
172	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017 , 15, 30	8.5	12
171	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
170	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
169	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
168	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 498-505	2.2	176
167	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1688-1700	21.7	328
166	Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Journal of Neuro-Oncology</i> , 2017 , 134, 443-451	4.8	11
165	The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. <i>Clinical Epigenetics</i> , 2017 , 9, 46	7.7	13
164	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017 , 10, 589-598	4.9	13
163	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
162	Crizotinib Failure in a -Rearranged Inflammatory Myofibroblastic Tumor With an Emerging Kinase Domain Mutation.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-7	3.6	4
161	A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6040-6040	2.2	3
160	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0180489	3.7	12
159	The fate of BRCA1-related germline mutations in triple-negative breast tumors. <i>American Journal of Cancer Research</i> , 2017 , 7, 98-114	4.4	4
158	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2017 , 37, 2323-2334	2.3	6
157	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017 , 37, 2947-2957	2.3	5
156	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017 , 14, 181-195	3.3	19

155	The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. <i>BMC Neurology</i> , 2016 , 16, 190	3.1	11
154	Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 164-9	3.8	18
153	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016 , 16, 291-298.e3	3	9
152	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 704-13	12.9	138
151	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <i>PLoS ONE</i> , 2016 , 11, e0164013	3.7	4
150	Disease evolution and heterogeneity in bilateral breast cancer. <i>American Journal of Cancer Research</i> , 2016 , 6, 2611-2630	4.4	4
149	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016 , 7, 5074-87	3.3	44
148	Overview of advances in cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016 , 4, 260	3.2	1
147	Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. <i>Anticancer Research</i> , 2016 , 36, 6347-6356	2.3	1
146	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016 , 7, 32731-53	3.3	25
145	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016 , 11, e0163138	3.7	8
144	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 307-21	4.4	12
143	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016 , 14, 136	8.5	17
142	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 117-31	4.4	17
141	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
140	Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. <i>Cancer Medicine</i> , 2016 , 5, 17-23	4.8	13
139	HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. <i>Anticancer Research</i> , 2016 , 36, 1581-90	2.3	
138	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016 , 36, 2365-78	2.3	5

137	p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab. <i>Pathology and Oncology Research</i> , 2015 , 21, 273-82	2.6	8
136	CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. <i>Cancer Genetics</i> , 2015 , 208, 129-34	2.3	7
135	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology, The</i> , 2015 , 16, 645-55	21.7	453
134	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1289-301	3.5	6
133	Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015 , 23, 60-70	1.9	3
132	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2	17
131	Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 384	4.8	38
130	Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2015 , 23, 2045-51	3.9	22
129	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015 , 13, 171	8.5	11
128	Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 1145-52	4.6	4
127	Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. <i>PLoS ONE</i> , 2015 , 10, e0124612	3.7	18
126	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015 , 10, e0140293	3.7	26
125	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	30
124	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 304-11 ²		435
123	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015 , 33, 723-31	2.2	100
122	Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. <i>Pharmacogenomics</i> , 2015 , 16, 79-94	2.6	21
121	Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA. <i>PLoS ONE</i> , 2015 , 10, e0128818	3.7	13
120	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2015 , 35, 4023-36	2.3	6

119	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Histology and Histopathology</i> , 2015 , 30, 1129-41	1.4	2
118	Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 330-8	3	9
117	A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). <i>BMC Cancer</i> , 2014 , 14, 111	4.8	16
116	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014 , 35, 1012-9	4.6	121
115	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. <i>BMC Cancer</i> , 2014 , 14, 515	4.8	22
114	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <i>BMC Clinical Pathology</i> , 2014 , 14, 28	3	10
113	Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2014 , 190, 636-8, 640-5	4.3	24
112	EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 737-48	4.9	29
111	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
110	Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). <i>PLoS ONE</i> , 2014 , 9, e94273	3.7	36
109	Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. <i>PLoS ONE</i> , 2014 , 9, e103707	3.7	3
108	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014 , 23, 234-43	3.6	22
107	FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 14-26.e1	3.8	13
106	Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. <i>Oral Oncology</i> , 2014 , 50, 298-305	4.4	21
105	A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. <i>PLoS ONE</i> , 2014 , 9, e86375	3.7	3
104	Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. <i>PLoS ONE</i> , 2014 , 9, e91407	3.7	11
103	In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. <i>PLoS ONE</i> , 2014 , 9, e99131	3.7	16
102	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. <i>BMC Cancer</i> , 2013 , 13, 263	4.8	59

101	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> , 2013 , 13, 163	4.8	24
100	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. <i>BMC Cancer</i> , 2013 , 13, 49	4.8	84
99	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. <i>BMC Clinical Pathology</i> , 2013 , 13, 1	3	17
98	Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. <i>Molecular Cancer</i> , 2013 , 12, 57	42.1	39
97	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. <i>Journal of Neurology</i> , 2013 , 260, 1469-80	5.5	21
96	Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 141-54	5.1	15
95	DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome. <i>Pathology and Oncology Research</i> , 2013 , 19, 329-43	2.6	8
94	Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 245-55	3.5	38
93	The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 267-274.e2	3.8	14
92	Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2870-8	2.2	115
91	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
90	Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. <i>Psycho-Oncology</i> , 2013 , 22, 2009-15	3.9	20
89	Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 157-63	4	16
88	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 431-9	4.7	18
87	Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. <i>PLoS ONE</i> , 2013 , 8, e58182	3.7	21
86	Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. <i>PLoS ONE</i> , 2013 , 8, e69256	3.7	11
85	Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. <i>PLoS ONE</i> , 2013 , 8, e70429	3.7	31
84	Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. <i>PLoS ONE</i> , 2013 , 8, e54048	3.7	33

83	Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013 , 8, e70634	3.7	13
82	Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. <i>Anticancer Research</i> , 2013 , 33, 2139-45	2.3	12
81	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 533-46	3.5	21
80	The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research</i> , 2012 , 14, 103-11	8.3	30
79	Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Epidemiology</i> , 2012 , 27, 857-66	12.1	14
78	XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. <i>BMC Cancer</i> , 2012 , 12, 271	4.8	54
77	Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). <i>BMC Cancer</i> , 2012 , 12, 342	4.8	16
76	Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. <i>Journal of Translational Medicine</i> , 2012 , 10, 212	8.5	28
75	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 77	12.8	18
74	Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. <i>PLoS ONE</i> , 2012 , 7, e37946	3.7	49
73	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <i>Journal of Translational Medicine</i> , 2012 , 10, 10	8.5	40
72	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 353-62	4.4	73
71	Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 603-14	4.7	13
70	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 609-19	4.4	39
69	Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. <i>Clinical Breast Cancer</i> , 2012 , 12, 183-93	3	43
68	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Oncology Reports</i> , 2012 , 27, 216-24	3.5	11
67	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. <i>Cancer Research</i> , 2012 , 72, 1795-803	13.1	93
66	Prognostic utility of Eubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 179-93	4.4	31

65	STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. <i>Translational Oncology</i> , 2011 , 4, 47-58	4.9	8
64	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011 , 43, 1210-4	36.3	253
63	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. <i>Cancer Research</i> , 2011 , 71, 6240-9	10.1	100
62	Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. <i>Anticancer Research</i> , 2011 , 31, 3007-18	2.3	24
61	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
60	Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. <i>Clinical Cancer Research</i> , 2010 , 16, 2427-34	12.9	52
59	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. <i>Journal of Translational Medicine</i> , 2010 , 8, 108	8.5	18
58	Bevacizumab in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2010 , 36, 75-82	14.4	15
57	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , 2010 , 11, 753-62	21.7	1653
56	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 649-60	3.5	52
55	The upgraded role of HER3 and HER4 receptors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 73-8	7	62
54	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. <i>Journal of Oncology</i> , 2009 , 2009, 305908	4.5	25
53	Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. <i>PLoS ONE</i> , 2009 , 4, e7746	3.7	68
52	Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 939-44	2.2	90
51	Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. <i>Oncology</i> , 2009 , 77, 107-12	3.6	23
50	Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 6454-61	12.9	83
49	Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4068-75	2.2	167
48	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 131-43	4.4	53

47	Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. <i>Oncology</i> , 2009 , 76, 275-85	3.6	33
46	Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. <i>BMC Cancer</i> , 2008 , 8, 234	4.8	74
45	Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Cancer Investigation</i> , 2008 , 26, 491-8	2.1	6
44	Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. <i>Cancer Investigation</i> , 2008 , 26, 784-93	2.1	58
43	Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 431-41	4.4	36
42	G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 377-85	4.4	35
41	DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study. <i>Open Medicine (Poland)</i> , 2008 , 3, 29-39	2.2	
40	Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. <i>Clinical and Experimental Metastasis</i> , 2007 , 24, 79-86	4.7	24
39	Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Oncology</i> , 2007 , 72, 388-96	3.6	15
38	Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. <i>European Journal of Cancer</i> , 2007 , 43, 443-53	7.5	43
37	Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. <i>Medical Oncology</i> , 2006 , 23, 479-88	3.7	7
36	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006 , 96, 251-61	4.4	38
35	Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. <i>Anticancer Research</i> , 2006 , 26, 4675-86	2.3	13
34	Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. <i>Medical Oncology</i> , 2005 , 22, 269-79	3.7	7
33	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. <i>BMC Cancer</i> , 2005 , 5, 25	4.8	45
32	Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. <i>Strahlentherapie Und Onkologie</i> , 2005 , 181, 222-28	4.3	20
31	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 1-9	4.4	29
30	Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Cancer Investigation</i> , 2004 , 22, 655-62	2.1	34

29	Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. <i>Medical Oncology</i> , 2004 , 21, 95-107	3.7	78
28	Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 57-67	2.7	1
27	Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. <i>Clinical Breast Cancer</i> , 2003 , 4, 120-5	3	93
26	G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. <i>Cancer</i> , 2001 , 91, 909-917	6.4	14
25	Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. <i>Cancer Investigation</i> , 2001 , 19, 137-44	2.1	4
24	Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3101-7	2.2	156
23	BRCA1 mutation analysis in breast/ovarian cancer families from Greece. <i>Human Mutation</i> , 2000 , 16, 272-3	3.7	26
22	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 313-9	4.7	6
21	Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Oncology</i> , 2000 , 58, 227-36	3.6	16
20	A Randomized Open-Label Parallel-Group Study Comparing Ondansetron with Ondansetron plus Dexamethasone in Patients with Metastatic Breast Cancer Receiving High-Dose Epirubicin. A Hellenic Cooperative Oncology Group Study. <i>Tumori</i> , 2000 , 86, 37-41	1.7	8
19	Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. <i>Cancer Investigation</i> , 2000 , 18, 503-9	2.1	54
18	Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. <i>Journal of Neuro-Oncology</i> , 1999 , 45, 159-65	4.8	13
17	Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. <i>International Journal of Cancer</i> , 1999 , 80, 810-7	7.5	27
16	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. <i>Clinical and Experimental Metastasis</i> , 1998 , 16, 665-72	4.7	15
15	Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes. A feasibility study. <i>Oncology</i> , 1998 , 55, 508-12	3.6	15
14	Accelerated Bifractionated Radiation with Concurrent Cisplatin Administration in Locally Advanced Head and Neck Cancer: A Feasibility Study. <i>Tumori</i> , 1997 , 83, 735-739	1.7	2
13	Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study. <i>Medical and Pediatric Oncology</i> , 1997 , 28, 401-10		11
12	Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study. <i>Cancer Investigation</i> , 1996 , 14, 189-96	2.1	5

11	Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study. <i>Journal of Laryngology and Otology</i> , 1996 , 110, 857-61	1.8	8
10	Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. <i>Neurosurgery</i> , 1996 , 39, 57-61; discussion 61-2	3.2	46
9	Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. <i>Medical and Pediatric Oncology</i> , 1996 , 26, 305-17		17
8	High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. <i>Medical and Pediatric Oncology</i> , 1995 , 24, 23-8		7
7	Evaluation of six tumor markers in patients with carcinoma of unknown primary. <i>Medical and Pediatric Oncology</i> , 1994 , 22, 162-7		41
6	Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study. <i>Acta Oncologica</i> , 1994 , 33, 825-30	3.2	23
5	Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Acta Oncologica</i> , 1993 , 32, 37-41	3.2	6
4	Carboplatin and Oral Etoposide in the Treatment of Patients with Advanced Breast Cancer Refractory to Anthracyclines. <i>Tumori</i> , 1993 , 79, 389-392	1.7	5
3	High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast Cancer. <i>Tumori</i> , 1991 , 77, 232-236	1.7	12
2	Carboplatin, Continuous Infusion Fluorouracil and Mid-cycle High-dose Methotrexate as Initial Treatment in Patients with Locally Advanced Head and Neck Cancer. <i>Tumori</i> , 1991 , 77, 426-431	1.7	7
1	Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. <i>Cancer</i> , 1990 , 66, 1453-60	6.4	23